This study is for people with certain blood cancers that have come back or not responded to treatment. It's called a Phase Ia/Ib study, which means it's the first time humans are trying this new medicine, SG2501. The study will help scientists see if it's safe and how it affects the body. The first part (Phase Ia) will test different doses to find the safest one, and the second part (Phase Ib) will test this dose on more people to see how well it works.

To join, you must be 18 or older, have a specific type of blood cancer, and meet other health requirements. You cannot join if you have certain health issues, like brain tumors or severe heart problems. You also need to be willing to visit the study site for tests and follow-ups.

• This study involves multiple visits and may last several weeks.
• Participants will receive the study medicine, SG2501.
• There may be risks, including side effects that are not yet known.

If you meet the criteria and are interested, you will need to provide your consent and follow the study rules. Make sure to discuss with your doctor to see if it's right for you.